IB Acquisition Corp.

• Company name, form and purpose

  • IB Acquisition Corp. — a blank-check (special purpose acquisition) company formed July 7, 2020 (Delaware) and converted to a Nevada corporation on September 21, 2023.
  • Purpose: effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination (an “initial business combination”).

• Headquarters and contact

  • Principal executive office: 1200 N Federal Highway, Suite 215, Boca Raton, FL 33432.
  • Telephone: (214) 687-0020.

• Corporate and listing details

  • Securities: common stock trading under ticker IBAC (Nasdaq) and rights trading under ticker IBACR (Nasdaq).
  • As of December 29, 2025: 5,739,970 shares of common stock issued and outstanding.
  • The company is identified in its 10‑K as a shell company.

• Status, timeline and liquidation provisions

  • The company has not completed an initial business combination and, as of the filing, had not selected or engaged in substantive discussions with any target.
  • Combination period: initially 24 months from the IPO; the board and stockholders approved an extension on September 22, 2025 extending the deadline to March 28, 2026.
  • If an initial business combination is not completed by the applicable deadline, the company will (i) cease operations except to wind up, (ii) redeem public shares for their pro rata share of the trust account and (iii) liquidate, subject to applicable law.

• Business strategy and acquisition criteria (stated facts)

  • No industry exclusivity; stated areas of focus include consumer goods, sports & entertainment, fintech, healthcare and life sciences.
  • Geographic focus stated as North America, Europe and Asia.
  • Target enterprise value: the company states it intends to seek targets with enterprise value of at least $500 million.
  • Nasdaq requirement noted: any initial business combination must (while listed) involve target(s) whose aggregate fair market value is at least 80% of the assets in the trust account (as described in the filing).

• Management and board (reported persons and summary credentials)

  • Adelmo “Al” Lopez — Chairman and Chief Executive Officer. Background references in filing: founder of Alma Coffee; former President & CEO of Blair Corporation; former CFO of Dole Fresh Fruit International.
  • Christy Albeck — Chief Financial Officer. Founder/Managing Member of Albeck Advisors; prior founder/CEO of Albeck Financial Services; former partner with Calabrese Consulting.
  • John Joyce — Vice Chairman. Former CFO of IBM; President of Asia Pacific and Head of Global Services at IBM; former Managing Director of SilverLake Partners.
  • Silvia Panigone — Director. CEO of Inhalis Therapeutics; founder of ADYA; former COO at NLS (NLSP).
  • Jian Zhang — Director. CEO and Managing Partner of Yuunnan Xiaosen Venture Capital Co., Ltd.; CEO of Hangzhou Hechuang Investment Management Co., Ltd.
  • Feng Xiangkun — Advisor. Former analyst/fund manager roles at State Grid Yingda and YuanDeKun; described as bringing securities experience and an Asian network.

• Sponsor, founder and pre-IPO holdings (stated facts)

  • Sponsor: I-B Good Works 4, LLC.
  • Founder shares: sponsor purchased 3,243,590 founder shares for an aggregate of $3,000 (approx. $0.0009 per founder share).
  • Private placement: sponsor purchased 610,500 private placement units for $6,105,000 (sold simultaneously with IPO).
  • Representative shares stated in the filing: 395,000 (referenced in share-total disclosures).

• Shares and ownership snapshots included in filing

  • Example breakdown (reported in the filing): public shares 1,490,880; founder shares 3,243,590; private placement shares 610,500; representative shares 395,000; total 5,739,970 (this equals the issued and outstanding amount as of Dec 29, 2025).
  • Market value (reported): aggregate market value of the company’s voting and non-voting common stock held by non-affiliates as of March 31, 2025 was $14,835,000.

• Trust account, IPO proceeds and fees (stated facts)

  • The filing states funds available for a business combination initially in the amount of $115,575,000 assuming no redemptions (the filing also notes this figure includes up to $4,025,000 for the M&A fee payable to I‑Bankers).
  • M&A fee: the filing elsewhere states the M&A fee to I‑Bankers is 3.5% of the gross proceeds of the IPO; a finder’s fee of 1.0% of consideration issued to a target is also described for targets introduced by I‑Bankers.
  • 2025 Special Meeting / redemptions: on September 22, 2025 stockholders holding 10,009,120 shares exercised redemption rights for approximately $10.60 per share; the filing reports approximately $106.1 million was removed from the trust account to pay such holders, “leaving approximately $15.8 million remaining in the Trust Account” (as stated in the filing). The filing also references the trust-account per‑share amount initially anticipated at approximately $10.05 per public share.

• Employees, operations, customers, revenue and income (explicit statements)

  • Employees: the filing states the company “currently has two executive officers.”
  • Operations and customers: the company is a blank‑check company with no operating business; it states it has not commenced operations other than its formation and the IPO activities and has not selected any target business (the filing explicitly states there is no specific business combination under consideration).
  • Revenue and income: the filing states the company has no operating history and no revenues; there are no reported revenues or operating income in the descriptive portions provided.

• Other corporate facts called out in the filing

  • Emerging growth company: the company states it is an “emerging growth company” under the JOBS Act and expects to take advantage of the related reduced reporting requirements.
  • No audit/internal control attestation reported: the box regarding a 404(b) attestation by auditors is unchecked in the filing’s cover page protections.
  • Legal proceedings: the filing states there is no material litigation, arbitration or governmental proceeding currently pending against the company or any members of management in their capacities as such.

(Everything above is drawn only from the text provided in your Form 10‑K excerpt. No assumptions or outside information have been added.)